Abstract. Biocatalysis has widened its scope and relevance since new molecular tools, including 18 improved expression systems for proteins, protein and metabolic engineering, and rational techniques for 19 immobilization, have become available. However, applications are still sometimes hampered by low 20 productivity and difficulties in scaling up. A practical and reasonable step to improve the performances 21 of biocatalysts (including both enzymes and whole-cell systems) is to use them in flow reactors. This 22 review describes the state of the art on the design and use of biocatalysis in flow reactors. The 23 encouraging successes of this enabling technology are critically discussed, highlighting new 24 opportunities, problems to be solved and technological advances. 25 26
Biocatalysis in flow reactors: why? 27
Bioprocesses (including biocatalysis) and continuous processing have been identified as the foremost 28 key green research areas for sustainable manufacturing from pharmaceutical and fine chemicals 29 industries [1] . Biocatalysis has widened its scope and application thanks to the massive advances in 30 protein and metabolic engineering, together with biocatalyst immobilization [2] . The performances of a 31 single enzyme can be improved in terms of substrate scope, operational stability and selectivity by 32 advanced protein engineering, whereas biosynthetic pathways can be engineered in suitable microbial 33 hosts leading to the preparation of molecules of different degree of complexity starting from cheap and 34 largely available natural substrates (metabolic engineering). Biocatalysis is now a reliable tool to develop 35 green and intensified processes, as long as proper reactor configurations are designed. Biocatalysis is 36 customarily carried out in batch reactors, which are flexible and simple. However, biocatalysis in 37 continuous flow reactors can be more productive, controlled and environmentally sustainable [3, 4] . 38
Specifically, flow chemistry (see Glossary) has rapidly developed both at industrial and academic level 39 [5] [6] [7] [8] , encompassing the design of compact and reconfigurable manufacturing platform for the synthesis, 40
and even formulation, of active pharmaceutical ingredients [9, 10] . 41
The transition from batch to continuous flow micro-and meso-reactors involves other two key concepts 42 of modern industrial biotechnology: green chemistry and process intensification (see Glossary) [11] . 43 Flow processing has the potential to accelerate biotransformations due to enhanced mass transfer, making 44 large-scale production more economically feasible in significantly smaller equipment with a substantial 45 decrease in reaction time, from hours to a few minutes, and improvement in space-time yield, with 46 increases of up to 650-fold as compared to batch processes. The small dimensions of the reactors 47 facilitated control of the reaction parameters, which can result in improved yields and productivities [12] . 48
Better process control makes the reaction more efficient and waste generation is minimized. The modular 49 nature of flow reactors also enables for the flexible increase of production volume by simply numbering-50 4 flow rate to the profile of enzyme deactivation, so that the quality of product concentration stays constant. 75
A window of operation to evaluate the effective use of immobilized biocatalysts has been suggested 76 based on the turnover number (tn), defined as the amount of product formed per amount of catalyst used 77 [94, 95] . Janssen and co-workers suggested that if the tn of a catalyst is too low, immobilization is not 78 economically viable [94] . On the other hand, the tn may be very high, or the products may have high 79 added value, resulting in catalyst costs under 0.05% of the added value. In this case, catalyst recycling is 80 generally not justifiable. However, if a tn falls within these limits then enzyme immobilization is 81 adequate. Additionally, the impact of catalyst costs on the product costs can be estimated based on the 82 total turnover number (ttn), defined as the moles of product formed (or of substrate converted) per mole 83 of catalyst employed. Accordingly, the ttn should exceed 1000 for high-value compounds produced at 84 small scale, or 50000 for commodity goods [95] . The biocatalyst half-life (time required to reduce its 85 activity to 50%) is a key parameter and can be determined under operational conditions [95] . Again, there 86 is no gold standard for enzyme half-life, it is factored in the cost of the process. 87 88 89
Working principles in of biocatalysis in flow reactors 90
The market accessibility of automated and easy-to-control instrumentation for flow chemistry has 91 increased in recent years, making controlled and reproducible work feasible. Different companies (e.g., 92
Vapourtec Ltd, Corning, Syrris, ThalesNano Nantechnology Inc., Accendo Corporation, AM 93
Technology, Uniqsis Ltd, Future Chemistry Holding BV, Chemtrix BV, Advion Inc., Ehrfeld, and YMC 94
Co. Ltd) offer now modules for micro-and meso-fluidic flow chemistry at lab scale. 95
The main components of a flow reactor for biocatalysis are schematically represented in Figure 1 (IMERs) and free enzyme reactors (FERs) are the most common because cell-free systems offer 151 advantages versus the whole-cell approach such as generally faster flow and lack drawbacks such as the 152 additional barriers between the substrate(s) and the catalyst, the possibility of side reactions, and the need 153 to maintain the cell wall integrity. Whole-cell biotransformations are particularly advantageous for co-154 factor depending enzymes, as the presence of native metabolic pathways, as well as endogenous 155 cofactors, can make these processes self-sufficient. Whole cells can be used in a tubular reactor (or in a 156 back-mix reactor), but to avoid washout during continuous operation and simplify cell recycle and 157 downstream processing they can be immobilized (immobilized whole cells reactors, IWCRs). given their non-invasive, non-destructive nature, and footprint compatible with microfluidic devices [45] . 211
In reactions where some parameters (such as oxygen or pH) can change, on-line monitoring is preferable, 212
as it provides a direct measure of the progress of the reaction. This issue was recently successfully 213 addressed by Gruber and colleagues, who used an optical pH sensor layer integrated in a microfluidic 214 side-entry reactor to measure the pH at multiple points in narrow channels. This sensor could map the 215 progression of a transketolase-and a penicillin G acylase-catalyzed reaction and constantly adjust the pH 216 in the enzymatic reaction [46] . 217 (Table I) . 223 Table I successfully scaled up to 10 L using a dynamically mixed flow reactor, which avoided the accumulation 361 of solids and blockage of the system [12, 84] . This resulted in reduced cost of capital equipment, lower 362 operating costs, and reduced catalyst consumption, due to faster throughput, for manufacturing processes. 363
Finally, Table 1 
Concluding Remarks and Future Perspectives 368
Recently, Sheldon and Pereira introduced the concept of "biocatalysis engineering", which combines and 369 entails the "engineering" of the different elements composing a biocatalytic process as a whole 
